PRINCETON, N.J.--( BUSINESS WIRE )-- Advaxis, Inc.  (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that its Board of Directors has approved a one-for-fifteen (1-for-15) reverse stock split of

Currently in a Phase 3 Pivotal Study for High-Risk Locally Advanced Cervical Cancer "Non-Hemolytic LLO Fusion Proteins and Methods of Utilizing Same." PRINCETON, N.J.--( BUSINESS WIRE )-- Advaxis, Inc.    (NASDAQ: ADXS)  (the Company),   a late-stage biotechnology company focused on the discovery,

"We continue to be very excited about our ADXS-HOT program and anticipate filing two additional INDs for drug constructs from this program during 2019." PRINCETON, N.J.--( BUSINESS WIRE )-- Advaxis, Inc.  (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and

PRINCETON, N.J.--( BUSINESS WIRE )-- Advaxis, Inc.  (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announced today two poster presentations at the upcoming American Association for Cancer Research (AACR)

"The ADXS-HOT program supports our goal of leveraging the significant experience we have gained from our proprietary platform in order to advance programs in the fight against cancer for patients in need of new therapeutic options and we look forward to studying these constructs in the clinic."

"These preliminary data suggest our approach may be among the best-in-class for CD8+ T cell response which we believe is important for successful clinical outcomes." PRINCETON, N.J.--( BUSINESS WIRE )-- Advaxis, Inc.  (NASDAQ:ADXS), (the Company) a late-stage biotechnology company focused on the

PRINCETON, N.J.--( BUSINESS WIRE )-- Advaxis, Inc.  (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that an overview of the Company’s proprietary  Lm  platform and new information regarding the

"Neoantigen prioritization for use in a Listeria monocytogenes cancer vaccine" PRINCETON, N.J.--( BUSINESS WIRE )-- Advaxis, Inc.    (NASDAQ:ADXS) , a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that two

Enrolled Patients Continue to be Treated "FDA’s review of the AXAL Investigational New Drug (IND) application was prompted by our proposal to modify the AIM2CERV trial’s analysis plan to include, among other things, allowance for a second formal interim analysis for both safety and efficacy" "FDA’s

Conference call to be held Tuesday, January 15, 2019 at 11am ET "Fiscal 2018 was an eventful year for Advaxis as we worked to reorganize the company, prioritize our pipeline and define a strategic direction that supports our mission to improve the lives of people suffering from cancer and their